A PHASE 1B, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF CERGUTUZUMAB AMUNALEUKIN, AN IMMUNOCYTOKINE, WHICH CONSISTS OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN

Protocol: 
AAAR5186
Phase: 
I

A PHASE 1B, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF CERGUTUZUMAB AMUNALEUKIN, AN IMMUNOCYTOKINE, WHICH CONSISTS OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN

The purpose of this study is to test the safety of the study drugs and how
well your body tolerates it. The study will also test how well the study
drugs work to slow down the growth of you tumor or stop your cancer. The
study drugs are Cergutuzumab Amunaleukin and Atezolizumab.

Atezolizumab is FDA approved for the treatment of patients with metastatic
non-small cell lung cancer. Cergutuzumab Amunaleukin is an investigational
new drug that has not been approved for treatment.

Are you Eligible? (Inclusion Criteria)

You must:
1. Be ≥ 18 years of age
2. Have confirmed locally advanced and/ or metastatic solid tumor
3. Have radiologically measurable and clinically evaluable disease
4. Have a life expectancy of ≥ 12 weeks

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States